Summary Recent clinical trials have suggested that a combination of folinic acid and 5-fluorouracil (5-FU) may improve response rates and survival in patients with advanced colorectal cancer. However, this regimen has been complicated by potentially life threatening toxicity. Regional delivery of folinic acid via a hepatic artery catheter might be expected to reduce systemic exposure and subsequent adverse effects.
The outlook for patients with colorectal liver metastases remains depressing; the mean survival for patients in the West of Scotland is approximately 3 months (Wood et al., 1976) . The results of systemic chemotherapy have been disappointing. Average response rates of only 10-15% have been reported following treatment with 5-FU and response has not been accompanied by increased survival (Kemeny, 1983) . These reports have lead to a third of surgeons in England and Wales opting not to actively treat patients with nonresectable colorectal liver metastases (Karanjia et al., 1990) and trials in the UK continue to include 'no active treatment' control arms (Hunt et al., 1990) .
Recent studies, however, have suggested that the addition of folinic acid may significantly improve survival amongst advanced colorectal cancer patients receiving 5-FU (Erlichman, 1988 , Poon et al., 1989 Kerr, 1989) . Briefly, folinic acid enhances 5-FU activity by stabilising the binding of the 5-FU metabolite, fluorodeoxyuridine monophosphate, to the enzyme thymidylate synthase. Unfortunately, therapy has been complicated by systemic toxicity which can be occasionally life-threatening.
The rationale for regional chemotherapy is the delivery of high drug concentrations to the compartment harbouring the tumour with relatively less drug escaping into the systemic vascular compartment. There is a large literature on intrahepatic arterial administration of 5-FU and FUdR to patients with hepatic metastases from colorectal primary cancers. In summary, the data are suggestive that tumour response rates are higher comparing regional with systemic administration, but there is no convincing evidence that intra-arterial chemotherapy significantly prolongs survival.
The aim of the present study was to compare the pharmacokinetic profiles of intravenous and intra-hepatic arterial folinic acid in patients who were receiving a 24 h infusion of 5-FU via an indwelling hepatic artery catheter.
Patients and methods

Patients
Patients with biopsy-proven, metastatic, colorectal adenocarcinoma, confined to the liver were recruited. 
Treatment
Patients received a 24 h arterial infusion of 5-FU, 600 mg m-2 per week, for 6 consecutive weeks. On the fourth and sixth weeks of this regimen, folinic acid (100 mg m-2) was administered as a 2 h infusion. On one occasion the folinic acid was given intravenously and on the other occasion it was administered via the hepatic artery. 5-FU and folinic acid infusions were commenced simultaneously. The order of the route of folinic acid delivery was random.
Pharmacokinetic assessments Five ml of peripheral venous blood was sampled before each folinic acid infusion and at 1, 2, 2. 25, 2.5, 3, 4, 5, 6, 8, 14 and 26 h after commencement of the infusion. Blood was placed in tubes containing lithium heparin which were stored in ice. With minimal delay (less than 5 min) the blood was centrifuged at 5,000 r.p.m. for 5 min then the plasma was removed and stored at -20°C in light protected vials.
As folinic acid has the propensity to be oxidised, control experiments were performed, spiking blood samples with known quantities of folinic acid, to ensure that plasma folates were stable during collection and separation. Folinic acid degradation was always less than 10% under these conditions. Serum levels of folinic acid were assayed using a sensitive and specific HPLC assay system (inter and intra-assay coefficients of variation <5%) with a limit of detection of 50 ng ml-'. A C18 microbondapack (10 microns) (A, a, B, 13 ) corrected for duration of infusion.
Statistical methods
The data were analysed using the paired student's t-test.
Results
Patients
Six patients entered the study (four males, two females). Mean age was 61 years (range 39-75). Three patients had previous treatment for their metastases (two with mitomycin C and one with regional 9'Y-glass microspheres) but their disease had progressed despite these therapies.
Pharmacokinetics
The pharmacokinetic parameters for folinic acid are summarised in Table I 
Discussion
Regional infusion of 5-FU reduces systemic exposure to the drug and therefore diminishes systemic toxicity (Goldberg et al., 1990) . Our attempts, in the present study, to apply these principles to folinic acid administration have revealed a statistically significant regional advantage for the arterial route. The pharmacokinetic parameters following intravenous administration of folinic acid are similar to those described in previous studies (Straw et al., 1984; McGuire et al., 1988; Trave et al., 1988; Rustum, 1989) .
Intra-arterial infusion of folinic acid reduces the plasma AUC and end of infusion plasma concentration and increases its volume of distribution relative to intravenous administration. We are not sure why the volume of distribution is greater following loco-regional infusion but it is possible that this could be due to increased first pass folinic acid extraction by the liver. We plan to clarify this point by measuring drug concentrations in tumours and normal liver biopsies taken during peroperative folinic acid infusions.
There was a trend towards prolongation of drug half-life following arterial infusion, but this did not reach significance. Folinic acid is cleared predominantly by the liver by metabolism to 5 methyl tetrahydrofolate, however it was not (Goldberg et al., 1990) .
Although there is an apparent pharmacokinetic advantage, this is offset by the potential for catheter thrombosis. In our experience, which includes placement of hepatic artery catheters in more than 70 patients, 5-FU can be infused regionally without complications. However, the addition of regional folinic acid to this treatment regimen has been associated with catheter occlusion in three out of six patients so treated. This information is anecdotal and has not been the subject of a formal study but we believe that it is important to supply these data. There was no other apparent treatment related toxicity.
Clinically, there are two strategies to try to overcome the problem of systemic relapse following loco-regional therapy: combination of regional with systemic therapy or dose escalating the regional therapy until peripheral venous concentrations equal those which are achieved with conventional systemic treatment. We have decided to adopt the latter approach and we are currently undertaking a phase I trial of intravenous folinic acid in combination with a 24 h intrahepatic arterial infusion of 5-FU. The folinic acid schedule has been fixed and the dose of 5-FU will escalated until plasma concentrations are similar to those achieved with intravenous infusions. This should allow the generation of high levels within the liver, the site of predominant bulk disease, but maintain adequate systemic levels.
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